TG Therapeutics, Inc. (TGTX) Given Consensus Rating of “Buy” by Analysts
Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned an average rating of “Buy” from the thirteen brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $27.00.
TGTX has been the topic of several research reports. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $23.00 price objective on shares of TG Therapeutics in a research report on Monday, June 5th. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Saturday, June 17th. BidaskClub lowered shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 6th. Finally, Zacks Investment Research raised shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Thursday, July 13th.
Shares of TG Therapeutics (NASDAQ TGTX) traded up 1.27% on Friday, reaching $11.95. 768,812 shares of the company were exchanged. TG Therapeutics has a 12-month low of $4.10 and a 12-month high of $15.35. The company’s 50 day moving average is $11.50 and its 200 day moving average is $11.35. The firm’s market capitalization is $744.60 million.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.01. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. Analysts forecast that TG Therapeutics will post ($1.84) earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. raised its position in shares of TG Therapeutics by 152.8% in the first quarter. Goldman Sachs Group Inc. now owns 43,020 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 26,001 shares during the period. Bank of Montreal Can bought a new stake in shares of TG Therapeutics in the first quarter valued at approximately $443,000. Dupont Capital Management Corp bought a new stake in shares of TG Therapeutics in the second quarter valued at approximately $258,000. Two Sigma Securities LLC bought a new stake in shares of TG Therapeutics in the first quarter valued at approximately $325,000. Finally, Ameriprise Financial Inc. bought a new stake in shares of TG Therapeutics in the first quarter valued at approximately $1,291,000. 49.89% of the stock is currently owned by institutional investors.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.